Recombinant Anti-Melanoma antibody [HMB45 + M2-7C10 + M2-9E3] (ab732)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse recombinant multiclonal [HMB45 + M2-7C10 + M2-9E3] to Melanoma
- Suitable for: IHC-Fr, IHC-P, Flow Cyt
- Reacts with: Human
Overview
-
Product name
Anti-Melanoma antibody [HMB45 + M2-7C10 + M2-9E3]
See all Melanoma primary antibodies -
Description
Mouse recombinant multiclonal [HMB45 + M2-7C10 + M2-9E3] to Melanoma -
Host species
Mouse -
Tested applications
Suitable for: IHC-Fr, IHC-P, Flow Cytmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Rat -
Immunogen
Recombinant full length protein corresponding to Melanoma. HMB45 - Pigmented melanoma metastases from LN MART-1 - Recombinant human MART-1 protein
-
Epitope
HMB45 and MART-1 -
Positive control
- IHC-P: Metastatic melanoma in lymph node.
-
General notes
This cocktail is HMB45 + two different clones of MART-1[M2-7C10] + [M2-9E3]. HMB34 isotype: IgG1/kappa and both clones of MART-1: IgG2b + IgG2b
HMB-45 and MART-1 are coexpressed in the majority of melanomas, as well as uniquely expressed in certain cases. Thus, the HMB-45 and MART-1 cocktail is potentially more sensitive than HMB-45 or MART-1 alone. MART-1 is a cocktail of clones M2-7C10 and M2-9E3. The combination of HMB-45 and the MART-1 cocktail make this triple antibody cocktail a first-order pan melanoma screener.
This product was changed from ascites to tissue culture supernatant on 14/07/17. The following lots are from ascites and are still in stock as of 14/07/17 – GR313023 and GR3175007. Lot numbers higher than GR313023 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Please note that this antibody is an oligoclonal antibody. It is a cocktail of monoclonal antibodies that have been carefully selected. Oligoclonal antibodies have not only the specificity and batch-to-batch consistency of a monoclonal antibody, but also have the advantage of the sensitivity of a polyclonal antibody due to their ability to recognize multiple epitopes on an antigen.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituents: 97.5% Water, 0.99% BSA, 0.33% Tris HCl, 0.007% Hydrochloric acid, 0.04% Tween -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Primary antibody notes
HMB-45 and MART-1 are coexpressed in the majority of melanomas, as well as uniquely expressed in certain cases. Thus, the HMB-45 and MART-1 cocktail is potentially more sensitive than HMB-45 or MART-1 alone. MART-1 is a cocktail of clones DT101 and BC199. The combination of HMB-45 and the MART-1 cocktail make this triple antibody cocktail a first-order pan melanoma screener. -
Clonality
Recombinant Multiclonal -
Clone number
HMB45 + M2-7C10 + M2-9E3 -
Myeloma
unknown -
Isotype
IgG2b -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab732 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IHC-P | (1) |
1/100 - 1/200.
The staining intensity of this melanoma cocktail is enhanced by performing heat mediated antigen retrieval using a high pH buffer. The HMB-45 portion of this antibody will stain with citrate buffer, pH 6.0; however, data shows the MART-1 portion of this cocktail may be negative unless a high pH buffer is used. We therefore, strongly recommend that you do not use citrate buffer for this antibody cocktail. |
Flow Cyt |
Use at an assay dependent concentration. PubMed: 22147606
ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody. |
Notes |
---|
IHC-Fr
Use at an assay dependent concentration. |
IHC-P
1/100 - 1/200. The staining intensity of this melanoma cocktail is enhanced by performing heat mediated antigen retrieval using a high pH buffer. The HMB-45 portion of this antibody will stain with citrate buffer, pH 6.0; however, data shows the MART-1 portion of this cocktail may be negative unless a high pH buffer is used. We therefore, strongly recommend that you do not use citrate buffer for this antibody cocktail. |
Flow Cyt
Use at an assay dependent concentration. PubMed: 22147606 ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody. |
Target
-
Relevance
Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre existing benign nevus, which occurs most often in the skin but also may involve other sites. -
Cellular localization
Membrane; Single-pass membrane protein -
Database links
- Entrez Gene: 293890 Rat
- Omim: 605513 Human
- SwissProt: Q16655 Human
-
Alternative names
- Antigen LB39 AA antibody
- Antigen SK29 AA antibody
- MART1 antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (25)
ab732 has been referenced in 25 publications.
- Netanely D et al. Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns. Oncogene 40:1792-1805 (2021). PubMed: 33564068
- Catalano A et al. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers (Basel) 13:N/A (2021). PubMed: 33924486
- Lee RJ et al. Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. ESMO Open 5:N/A (2020). PubMed: 32817058
- Golan T et al. Adipocytes sensitize melanoma cells to environmental TGF-ß cues by repressing the expression of miR-211. Sci Signal 12:N/A (2019). PubMed: 31337739
- Li H et al. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression. Cell Rep 29:3200-3211.e4 (2019). PubMed: 31801083